Hypercalcemia may develop both spontaneously and as a result of androgen therapy in women with disseminated breast carcinoma. If it develops while on this agent, the drug should be discontinued. Caution is required in administering these agents to patients with cardiac, renal or hepatic disease. Cholestatic jaundice is associated with therapeutic use of anabolic and androgenic steroids. Edema may occur occasionally with or without congestive heart failure. Concomitant administration of adrenal steroids or ACTH may add to the edema. In children, anabolic steroid treatment may accelerate bone maturation without producing compensatory gain in linear growth. This adverse effect may result in compromised adult stature. The younger the child the greater the risk of compromising final mature height. The effect on bone maturation should be monitored by assessing bone age of the wrist and hand every six months. This drug has not been shown to be safe and effective for the enhancement of athletic performance. Because of the potential risk of serious adverse health effects, this drug should not be used for such purpose.
Treatment may involve the prescription of immunosuppressive glucocorticoids such as prednisone , with or without azathioprine , and remission can be achieved in up to 60–80% of cases, although many will eventually experience a relapse .  Budesonide has been shown to be more effective in inducing remission than prednisone , and result in fewer adverse effects.  Those with autoimmune hepatitis who do not respond to glucocorticoids and azathioprine may be given other immunosuppressives like mycophenolate , ciclosporin , tacrolimus , methotrexate , etc. Liver transplantation may be required if patients do not respond to drug therapy or when patients present with fulminant liver failure .